MONITORING DURING AND AFTER TREATMENT OF CANINE LEISHMANIOSIS

Recommended monitoring during and after treatment of CanL

PARAMETERS FREQUENCY
  Sick treated dogs Clinically healthy infected dogs
Clinical history and physical examination
CBC, biochemical profile ± serum electrophoresis
Complete urinalysis ±UPC
After the first month of treatment and then every 3-4 months during the first year.
Later on, every 6-12 months in dogs fully recovered clinically with treatment.
Every 3-6 months
Quantitative serology* Not before 6 months after initial treatment and every 6-12 months. Every 3-6 months
Real-time PCR (optional) At the same time as serology. Every 3-6 months
 

CBC: complete blood count; UPC: urinary protein:creatinine ratio.

* Some dogs have a significant decrease in antibody levels (i.e. more than three two-fold dilutions difference between monitoring samples) associated with clinical improvement within 6-12 months of therapy. A marked increase in antibody levels (i.e. more than three two-fold dilutions difference between monitoring samples) should be interpreted as a marker of disease relapse, especially in dogs following the discontinuation of treatment.

 

Management of Leishmania-seropositive but clinically healthy dogs (not vaccinated) and of PCR-positive but seronegative dogs

Management of all dogs with no clinical signs and laboratory abnormalities
 
 

It is recommended to use serology alone or the combination of serology with PCR for screening healthy dogs and to avoid screening clinically healthy dogs (not vaccinated) only by PCR.
Confirmed low seropositive dogs should be monitored with physical examinations, routine laboratory and serological tests on a regular basis every 3-6 months to assess the possible progression of infection towards disease.